Replies to post #485290 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

NWBO worth $50 on nGBM and rGBM indication fully diluted. No need for a reverse split. We will be at $10 after the journal brings larger buyers into NWBO. Family offices are not limited from buying on OTC as Hefner shows whereas a joint partnership that takes 20% of our float at $50 would be about 1 year of Keytruda and Opdivo revenue. Gilead paid about the same from Trodelvy. There's simply no reason to penalize shareholders with a reverse split when we hold all of the cards.